Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A. Werutsky G, et al. Among authors: smaletz o. BMC Cancer. 2019 May 23;19(1):487. doi: 10.1186/s12885-019-5709-y. BMC Cancer. 2019. PMID: 31122212 Free PMC article. Clinical Trial.
Castration-resistant prostate cancer: systemic therapy in 2012.
Maluf FC, Smaletz O, Herchenhorn D. Maluf FC, et al. Among authors: smaletz o. Clinics (Sao Paulo). 2012;67(4):389-94. doi: 10.6061/clinics/2012(04)13. Clinics (Sao Paulo). 2012. PMID: 22522765 Free PMC article. Review.
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
Smaletz O, Diz MD, do Carmo CC, Sabbaga J, Cunha-Junior GF, Azevedo SJ, Maluf FC, Barrios CH, Costa RL, Fontana AG, Madrigal V, Wainstein AJ, Yeda FP, Alves VA, Moro AM, Blasbalg R, Scott AM, Hoffman EW. Smaletz O, et al. Gynecol Oncol. 2015 Aug;138(2):272-7. doi: 10.1016/j.ygyno.2015.05.023. Epub 2015 May 27. Gynecol Oncol. 2015. PMID: 26026738 Clinical Trial.
First Brazilian Consensus of Advanced Prostate Cancer: Recommendations for Clinical Practice.
Sasse AD, Wiermann EG, Herchenhorn D, Bastos DA, Schutz FA, Maluf FC, Coura G Filho, Morbeck IAP, Cerci JJ, Smaletz O, Lima VS, Adamy A Jr, Campos FS, Carvalhal GF, Cezar LC, Dall'Oglio MF, Sadi MV, Reis RBD, Nogueira L. Sasse AD, et al. Among authors: smaletz o. Int Braz J Urol. 2017 May-Jun;43(3):407-415. doi: 10.1590/S1677-5538.IBJU.2016.0490. Int Braz J Urol. 2017. PMID: 28199075 Free PMC article.
Second brazilian consensus on the treatment of advanced prostate cancer - a SBOC-SBU-SBRT panel review.
Sasse AD, Dos Reis RB, Nogueira LM, Maluf FC, Herchenhorn D, Smaletz O, Lima VS, Schutz F, Bastos D, Wiermann EG, Morbeck IAP, Jardim LF, Souza VC, Carvalho IT, Leite ETT, Nardozza A Jr, Pompeo ACL, Bretas F, Leal MLO, Sadi MV, da Ponte JRT, Carvalhal GF. Sasse AD, et al. Among authors: smaletz o. Int Braz J Urol. 2019 May-Jun;45(3):449-458. doi: 10.1590/S1677-5538.IBJU.2018.0798. Int Braz J Urol. 2019. PMID: 31038861 Free PMC article.
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Free article. Clinical Trial.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. Sternberg CN, et al. N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469184 Clinical Trial.
Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study.
Maluf FC, de Oliveira FAM, Liedke PER, Brust L, Inocêncio CG, Monteiro FSM, Smaletz O, Cubero DI. Maluf FC, et al. Among authors: smaletz o. Clin Genitourin Cancer. 2021 Jun;19(3):e171-e177. doi: 10.1016/j.clgc.2020.12.008. Epub 2021 Jan 7. Clin Genitourin Cancer. 2021. PMID: 33610484 Clinical Trial.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
Maluf FC, Schutz FA, Cronemberger EH, Luz MA, Martins SPS, Muniz DQB, Bastos DA, Cárcano FM, Smaletz O, Soares A, Peixoto FA, Gomes AJ, Cruz FM, Franke FA, Herchenhorn D, Dos Santos TM, Fabricio VC, Gidekel R, Werutsky G, de Jesus RG, Souza VC, Fay AP. Maluf FC, et al. Among authors: smaletz o. Eur J Cancer. 2021 Oct 13;158:63-71. doi: 10.1016/j.ejca.2021.08.032. Online ahead of print. Eur J Cancer. 2021. PMID: 34655838 Free article.
35 results